Nutriband, Inhibrx leads healthcare gainers; Organogenesis, Trevi Therapeutics among major losers
- BySeeking Alpha-
Nutriband NTRBW +84%, Nutriband NTRB +38%, Organogenesis (ORGO) -17%, Trevi Therapeutics (TRVI) -11%
Symbol | Exchange | Currency |
|---|
Nutriband NTRBW +84%, Nutriband NTRB +38%, Organogenesis (ORGO) -17%, Trevi Therapeutics (TRVI) -11%
Trevi Therapeutics (TRVI) has entered into a definitive agreement with institutional investor, for the purchase of:(i) 2,373,201 common shares and accompanying warrants to...
Trevi Therapeutics (TRVI): Q2 Net Loss of $9.8MTotal cash and cash equivalents of $36.4MPress Release
Trevi Therapeutics, Inc. (NASDAQ:TRVI) has been struggling lately, but the selling pressure may be coming to an end soon. That is because TRVI recently saw a Hammer Chart Pattern...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Strong Buy | Neutral | Strong Sell |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Sell | Strong Sell |
| Summary | Strong Buy | Strong Buy | Strong Buy | Neutral | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 2,748.90 | 2,760.00 | 2,708.50 | -2.4 | -0.09% | 1.64M | NASDAQ | |||
| 328.69 | 329.56 | 319.72 | +4.08 | +1.26% | 32.42M | NASDAQ | |||
| 148.64 | 149.37 | 147.62 | -0.05 | -0.03% | 49.70M | NASDAQ | |||
| 168.51 | 169.00 | 165.86 | +1.22 | +0.73% | 213.79K | NASDAQ | |||
| 49.41 | 50.07 | 49.31 | -0.05 | -0.10% | 42.70M | NASDAQ | |||
| 231.66 | 233.55 | 227.70 | +4.40 | +1.94% | 22.54M | NASDAQ | |||
| 176.17 | 178.28 | 173.83 | -1.53 | -0.86% | 11.90M | NYSE | |||
| 81.66 | 81.72 | 79.95 | +0.51 | +0.63% | 9.13M | NYSE | |||
| 43.15 | 43.24 | 42.57 | -0.01 | -0.02% | 17.60M | NYSE | |||
| 671.66 | 675.88 | 657.07 | +6.88 | +1.03% | 3.78M | NASDAQ | |||
| 325.54 | 327.00 | 305.11 | +24.70 | +8.21% | 8.29M | NASDAQ | |||
| 349.56 | 350.06 | 323.27 | +23.02 | +7.05% | 9.62M | NASDAQ | |||
| 27.69 | 28.13 | 27.67 | -0.17 | -0.61% | 1.37M | NYSE | |||
| 45.66 | 48.00 | 45.46 | -2.83 | -5.84% | 849.83K | NYSE | |||
| 34.88 | 35.04 | 32.90 | +2.18 | +6.67% | 23.41M | NASDAQ |
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, which is in Phase IIb/III clinical trial is an oral extended release formulation of nalbuphine that is used for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson’s disease, as well as to treat chronic kidney disease-associated with pruritus. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation; and Rutgers to develop and commercialize products incorporating nalbuphine for any human or animal use. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.